Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 1, 2020

BioPharm International

  • BioPharm International-05-01-2020
  • Volume 33
  • Issue 5

Supercritical Fluid Chromatography System

The Nexera UC Prep, a preparative supercritical fluid chromatography (SFC) system from Shimadzu, works to provide maximum use of lab resources through flexible system configurations in a compact design that requires low installation space.

The Nexera UC Prep, a preparative supercritical fluid chromatography (SFC) system from Shimadzu, works to provide maximum use of lab resources through flexible system configurations in a compact design that requires low installation space.

The system can be configured based on user specifications, which include chiral or achiral purifications, single injections, stacked injections, and fraction collections from microliters to liters. Additionally, the system comes equipped with LotusStream gas-liquid separator technology for high recovery and low carryover, and Prep Solution software for streamlining operations.

The SFC solution also reduces the need for solvents, shortens purification run time and dry down time, reduces the total size of the recovery system, and allows for easy rinsing.

Shimadzu

 

 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.